NovalGen announces one oral and two poster presentations at the American Society of Haematology Annual Meeting

NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside an auto-regulation platform, has announced the online publication of three abstracts submitted to the American Society of Haematology Annual meeting, to be held December 10-13, 2022.

Read the full story from NovalGen here.